HGF/c-Met related activation of -catenin in hepatoblastoma

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Purcell, Rachel ^a   Childs, Margaret ^b   Maibach, Rudolf ^c   Miles, Carina ^d   Turner, Clinton ^d   Zimmermann, Arthur ^e   Sullivan, Michael ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c SIAK Co ordinating Center   (Switzerland)

^d CANTERBURY HEALTH LABORATORIES   (New Zealand)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; SCATTER FACTOR; ANTINEOPLASTIC AGENT; CTNNB1 PROTEIN, HUMAN; DNA; MESSENGER RNA; RNA; SCATTER FACTOR RECEPTOR; TYROSINE;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CTNNB1 GENE; CYTOPLASM; GENE; GENE MUTATION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; INTERNATIONAL COOPERATION; LIVER TUMOR; METABOLISM; MULTICENTER STUDY; MUTATION; PHOSPHORYLATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; CARBOPLATIN; CELL NUCLEUS; CISPLATIN; COHORT STUDIES; CYTOPLASM; DNA, NEOPLASM; DOXORUBICIN; FOLLOW-UP STUDIES; HEPATOBLASTOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; INTERNATIONAL AGENCIES; LIVER NEOPLASMS; MUTATION; PHOSPHORYLATION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-MET; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TYROSINE;

EID: 80053927106     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-96     Document Type: Article

References (46)

1. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. [Review] [28 refs]. Perilongo G, et al. Lancet Oncology 2000 1 94 100 10.1016/S1470-2045(00)00018-8 11905674
2. Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Stiller CA, Pritchard J, Steliarova-Foucher E, European Journal of Cancer 2006 42 13 2115 23 10.1016/j.ejca.2006.05.011 16919775 (Pubitemid 44224056)
3. Beckwith-Wiedemann syndrome. Weksberg R, Shuman C, Beckwith JB, Eur J Hum Genet 2009 18 1 8 14
4. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. Hirschman BA, Pollock BH, Tomlinson GE, Journal of Pediatrics 2005 147 2 263 6 10.1016/j.jpeds.2005.04.019 16126064 (Pubitemid 41207846)
5. The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Zimmermann A, European Journal of Cancer 2005 41 11 1503 14 10.1016/j.ejca.2005.02.035 15982867 (Pubitemid 40981831)
6. Pediatric liver tumors and hepatic ontogenesis: common and distinctive pathways. Zimmermann A, Med Pediatr Oncol 2002 39 5 492 503 10.1002/mpo.10174 12228906
7. Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Honda S, et al. British Journal of Cancer 2008 99 11 1891 9 10.1038/sj.bjc.6604754 19034281
8. Loss of imprinting in hepatoblastoma. Rainier S, Dobry CJ, Feinberg AP, Cancer Research 1995 55 9 1836 8 7728748
9. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Lopez-Terrada D, et al. Hum Pathol 2009 40 6 783 94 10.1016/j.humpath.2008.07.022 19200579
10. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Adesina AM, et al. Hum Pathol 2009 40 6 843 53 10.1016/j.humpath.2008. 10.022 19200578
11. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Jeng YM, et al. Cancer Lett 2000 152 1 45 51 10.1016/S0304-3835(99)00433-4 10754205 (Pubitemid 30169017)
12. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Koch A, et al. Cancer Res 1999 59 2 269 73 9927029 (Pubitemid 29048850)
13. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Wei Y, et al. Oncogene 2000 19 4 498 504 10.1038/sj.onc.1203356 10698519 (Pubitemid 30099363)
14. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Yamaoka H, et al. Oncology Reports 2006 15 3 551 6 16465411
15. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Taniguchi K, et al. Oncogene 2002 21 31 4863 71 10.1038/sj.onc.1205591 12101426 (Pubitemid 34879463)
16. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Yamaoka H, et al. Oncol Rep 2006 15 3 551 6 16465411
17. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Blaker H, et al. Genes Chromosomes Cancer 1999 25 4 399 402 10.1002/(SICI)1098-2264(199908)25:4<399::AID-GCC14>3.0.CO;2-X 10398436 (Pubitemid 29326149)
18. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Takayasu H, et al. Clin Cancer Res 2001 7 4 901 8 11309340 (Pubitemid 32708728)
19. High frequency of beta-catenin mutations in hepatoblastoma. Udatsu Y, et al. Pediatr Surg Int 2001 17 7 508 12 10.1007/s003830000576 11666046 (Pubitemid 32896309)
20. beta-catenin destruction complex: insights and questions from a structural perspective. Kimelman D, Xu W, Oncogene 2006 25 57 7482 91 10.1038/sj.onc.1210055 17143292 (Pubitemid 44885747)
21. Convergence of Wnt, beta-catenin, and cadherin pathways. Nelson WJ, Nusse R, Science 2004 303 5663 1483 7 10.1126/science.1094291 15001769 (Pubitemid 38314410)
22. beta-Catenin is critical for early postnatal liver growth. Apte U, et al. Am J Physiol Gastrointest Liver Physiol 2007 292 6 1578 85 10.1152/ajpgi.00359. 2006 17332475 (Pubitemid 47080611)
23. Wnt/beta-catenin signaling in hepatic organogenesis. Nejak-Bowen K, Monga SP, Organogenesis 2008 4 2 92 9 10.4161/org.4.2.5855 19279720
24. Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis. Shang XZ, et al. Lab Invest 2004
25. Nuclear accumulation of beta-catenin without an additional somatic mutation in coding region of the APC gene in hepatoblastoma from a familial adenomatous polyposis patient. [Review] [40 refs]. Inukai T, et al. Oncology Reports 2004 11 1 121 6 14654913
26. beta-Catenin and met deregulation in childhood Hepatoblastomas. Ranganathan S, Tan X, Monga SP, Pediatric & Developmental Pathology 2005 8 4 435 47 10.1007/s10024-005-0028-5 22007284 (Pubitemid 41586881)
27. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Monga SP, et al. Cancer Res 2002 62 7 2064 71 11929826 (Pubitemid 34408453)
28. Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Zeng G, et al. Exp Cell Res 2006 312 18 3620 30 10.1016/j.yexcr.2006.08.003 16952352 (Pubitemid 44470779)
29. Targeting the c-Met signaling pathway in cancer. Peruzzi B, Bottaro DP, Clin Cancer Res 2006 12 12 3657 60 10.1158/1078-0432.CCR-06-0818 16778093 (Pubitemid 44000247)
30. The occurrence of liver growth factor in hepatoblastoma. von Schweinitz D, et al. Eur J Pediatr Surg 1998 8 3 133 6 10.1055/s-2008-1071139 9676393 (Pubitemid 28312047)
31. Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. von Schweinitz D, et al. Int J Cancer 2000 85 2 151 9 10629070 (Pubitemid 30023060)
32. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Danilkovitch-Miagkova A, et al. Mol Cell Biol 2001 21 17 5857 68 10.1128/MCB.21.17.5857-5868.2001 11486025 (Pubitemid 32737803)
33. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. Perilongo G, et al. N Engl J Med 2009 361 17 1662 70 10.1056/NEJMoa0810613 19846851
34. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. Zsiros J, et al. J Clin Oncol 2010 17 1B 561 7
35. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. [Review] [69 refs]. Buendia MA, Medical & Pediatric Oncology 2002 39 5 530 5 10.1002/mpo.10180 22007350
36. Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. Curia MC, et al. Modern Pathology 2008 21 1 7 14 10.1038/modpathol.3800977 17962810
37. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. Park WS, et al. J Pathol 2001 193 4 483 90 10.1002/1096- 9896(2000)9999:9999<::AID-PATH804>3.0.CO;2-R 11276007 (Pubitemid 32266817)
38. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Buendia MA, Med Pediatr Oncol 2002 39 5 530 5 10.1002/mpo.10180 12228912
39. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Maulik G, et al. Cytokine Growth Factor Rev 2002 13 1 41 59 10.1016/S1359-6101(01)00029-6 11750879 (Pubitemid 34436961)
40. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Cieply B, et al. Hepatology 2009 49 3 821 31 10.1002/hep.22695 19101982
41. beta-catenin signaling and cancer. Morin PJ, Bioessays 1999 21 12 1021 30 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P 10580987
42. Frequent beta-catenin overexpression without exon 3 mutation in cutaneous lymphomas. Bellei B, et al. Mod Pathol 2004 17 10 1275 81 10.1038/modpathol. 3800181 15195109 (Pubitemid 39312954)
43. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Fujimori M, et al. Cancer Res 2001 61 18 6656 9 11559529 (Pubitemid 32896480)
44. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Rimm DL, et al. Am J Pathol 1999 154 2 325 9 10.1016/S0002-9440(10)65278-9 10027390 (Pubitemid 29094082)
45. beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Wright K, et al. Int J Cancer 1999 82 5 625 9 10.1002/(SICI)1097-0215(19990827)82:5<625:: AID-IJC1>3.0.CO;2-2 10417756 (Pubitemid 29356957)
46. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Zeng G, et al. Neoplasia 2006 8 4 279 89 10.1593/neo.05607 16756720